Canopy Growth’s Next Step for Weed Domination

By Chris Lange Updated Jan 11, 3:41AM EST · Published Oct 2, 12:45PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Canopy Growth’s Next Step for Weed Domination — © Thinkstock

Canopy Growth Corp. (NYSE: CGC) shares dipped on Wednesday, following the markets lower after the firm announced that it will purchase a majority stake in a leading producer of sports nutrition products. Specifically, the weed giant is acquiring BioSteel Sports Nutrition in an all-cash transaction.

The transaction provides Canopy Growth with a significant platform to enter the sports nutrition and hydration segment, and it lays the groundwork for the adoption of cannabidiol (CBD) in future product offerings in accordance with regulations globally, including products to be sold in the United States containing CBD sourced from federally permissible industrial hemp.

This move accelerates Canopy Growth’s strategy to enter new markets with a platform spanning production, distribution and marketing of CBD products derived from hemp and cannabis in accordance with regulations across a number of different verticals. The transaction gives Canopy Growth a 72% stake in BioSteel with an agreed upon path to 100% ownership.

Additionally, BioSteel has national organizational partnerships with USA Hockey, Canada Basketball, Athletics Canada and the Professional Hockey Players Association. The company has over 10,000 points of distribution in Canada and the United States and continues to expand in both markets and into Europe.

[nativounit]

Mark Zekulin, CEO of Canopy Growth, commented:

BioSteel has a reputation for being a best-in-class provider of natural sports nutrition products and all of its products are well positioned to benefit from the increasing trend of plant-based and all-natural products, preferred not only by professional athletes, but active consumers as well. This acquisition allows us to enter the sports nutrition space with a strong and growing brand as we continue towards a regulated market of food and beverage products that contain cannabis. We view the adoption of CBD in future BioSteel offerings as a potentially significant and disruptive growth driver for our business.

Shares of Canopy Growth traded down about 2% to $21.40 on Wednesday, in a 52-week range of $20.52 to $59.25.

[recirclink id=581797]
[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.